WE PROPOSE TO DEVELOP A METHODOLOGY BY WHICH THE GENES CODING FOR AUTOIMMUNE DISEASE-SPECIFIC PROTEIN ANTIGENS CAN BE RAPIDLY CLONED USING RECOMBINANT DNA TECHNIQUES.

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$50,000.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
2910
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Collaborative Research Inc
128 Spring Street, Lexington, MA, 02173
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 DONALD WARREN BOWDEN
 PRINCIPAL INVESTIGATOR
 (617) 861-9700
Business Contact
Phone: () -
Research Institution
N/A
Abstract
WE PROPOSE TO DEVELOP A METHODOLOGY BY WHICH THE GENES CODING FOR AUTOIMMUNE DISEASE-SPECIFIC PROTEIN ANTIGENS CAN BE RAPIDLY CLONED USING RECOMBINANT DNA TECHNIQUES. THE SYSTEM WHICH WE ARE USING LENDS ITSELF TO HIGH-LEVEL EXPRESSION OF THESE ANTIGENS AS HYBRID PROTEINS IN E. COLI. THIS FACILITATES PRODUCTION OF THESE ANTIGENS FOR IN PHASE I A CDNA LIBRARY WILL BE CONSTRUCTED FROM HUMAN THYROID TISSUE. CLONING WILL BE INTO THE LAMBDA GT11 SYSTEM. CLONES CARRYING GRAVES-SPECIFIC SEQUENCES WILL BE IDENTIFIED BY DIFFERENTIAL IMMUNOSCREENING WITH SERA FROM GRAVES' PATIENTS AND SERA FROM NORMAL INDIVIDUALS. GRAVES' POSITIVE CLONES CAN BE INDUCED WITH THE LAMBDA GT11 SYSTEM, LEADING TO EXPRESSION OF SUBSTANTIAL AMOUNTS OF THE GRAVES' ANTIGEN FUSED TO BETA-GALACTOSIDASE (HYBRID PROTEIN). BECAUSE OF THEIR LARGE SIZE, THEY CAN SUBSEQUENTLY BE PURIFIED EASILY. IN PHASE II THE CLONED GRAVES' ANTIGENS WILL BE CHARACTERIZED. THEY WILL BE TESTED EXTENSIVELY FOR THE ABILITY TO BIND SPECIFICALLY WITH AUTOANTIBODIES PRESENT IN THE SERA FROM GRAVES' PATIENTS. CLONED ANTIGENS DETERMINED TO BE GRAVES-SPECIFIC WILL BE USED TO DEVELOP DIAGNOSTIC

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government